Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Want to cut your energy bills? Here’s how five experts are doing it 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
How Technology Is Reshaping Modern Business: From Operations to Customer Experience 
MIAMI, March 03, 2017 -- The Female Health Company / Veru Healthcare (NASDAQ:FHCO) today announced that it will host a conference call to update investors on the Company’s product commercialization and drug development progress on Thursday, March 9, 2017 at 10:30 a.m. Eastern Time (ET).
|
|||
The conference call will be available to interested parties by dialing 1-877-883-0383 from the U.S. or 1-412-902-6506 from international locations, participant entry number for all 9649925.
A replay of the conference call will be available beginning on Tuesday, March 14, 2017 through Tuesday, March 21, 2017, by dialing 1-877-344-7529 (international callers dial 1-412-317-0088) and entering the replay access code 10102781. After Tuesday, March 21, 2017, the replay of the call will be available on the Company’s website at www.fhcinvestor.com.
About The Female Health Company / Veru Healthcare
The Female Health Company / Veru Healthcare is a pharmaceutical and medical device company, with a focus on the development and commercialization of pharmaceuticals that qualify for the FDA's 505(b)(2) accelerated regulatory approval pathway as well as the 505(b)(1) pathway. The Company does business both as "Veru Healthcare" and as "The Female Health Company" and is organized as follows:
- Veru Healthcare manages the Pharmaceuticals Division, which develops and commercializes pharmaceutical products for men's and women's health and oncology.
- Veru Healthcare manages the Consumer Health / Medical Devices Division, which is focused on commercializing sexual healthcare products and devices for the consumer market, including the Company's FC2 Female Condom® in the consumer health products sector and PREBOOST® medicated individual wipes, which are a male genital desensitizing drug product that helps in the prevention of premature ejaculation.
- The Female Health Company manages the Global Public Health Division, which is focused on the global public health sector FC2 business. This division markets the Company’s Female Condom (FC2) to entities, including ministries of health, government health agencies, U.N. agencies, nonprofit organizations and commercial partners, that work to support and improve the lives, health and well-being of women around the world.
More information about The Female Health Company and its products can be found at www.femalehealth.com, www.veruhealthcare.com and www.femalecondom.org. For corporate and investor-related information about the Company, please visit www.FHCinvestor.com.
Contact: Kevin Gilbert: 312-366-2633
